CareLit · DOI-Nachweis · Klinische Pädiatrie
Immunomodulation following treatment with ch14.18 and interleukin 2 in patients with refractory neuroblastoma
DOI 10.1055/s-0031-1277094
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Brackrock, N Siebert, HN Lode
ZeitschriftKlinische Pädiatrie
Ausgabe05/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Patients with recurrent or refractory neuroblastoma are treated with ch14.18 and s.c. interleukin 2 (IL-2). Antibody is applied as continuous long term infusion in order to reduce side effects known to occur after bolus infusion. Here we describe effects of this therapy on the immune response. Methods: Patients received IL-2 for 5 days (s.c.; day 1–5), followed by a combined application of IL-2 (s.c.;…
Zitieren
Zitierempfehlung
D Brackrock, N Siebert, HN Lode (2011) Immunomodulation following treatment with ch14.18 and interleukin 2 in patients with refractory neuroblastoma. Klinische Pädiatrie (05). https://doi.org/10.1055/s-0031-1277094
Mit CareLit weiterarbeiten